Tapping into the full therapeutic potential of GLP-1

The therapeutic potential of targeting glucagon-like peptide-1 (GLP-1) has become notable as diabetes and weight loss drugs, and as drug candidates beyond insulin regulation. Looking beyond GLP-1 as a singular drug target and considering its multifaceted roles in metabolism may help scientists uncover treatment opportunities in cardiovascular and neurological diseases.

Explore a discussion between Dale Wright, executive director of inflammation and systems biology and Brian Bond, vice president of drug discovery and translational sciences at Inotiv, where they provide insight into the importance of taking a holistic approach to GLP-1 therapeutic research using systems pharmacology.